Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

FCB Health Europe takes aim at strategy development

Adds three new directors to the team

Sanofi reception

Dupixent helps put Sanofi back on growth track

French drugs giant sees an 8% rise in vaccine sales

- PMLiVE

Novartis culls pipeline to focus on most transformative science

Anti-infectives among areas hit by streamlining

- PMLiVE

Amgen CEO says Aimovig is “one of most successful launches”

Contrasts with cholesterol drug Repatha, its price slahed 60% to lift take-up

- PMLiVE

Digital Trials

A framework for success

- PMLiVE

The Healthcare Partnership is launched

Offers brand implementation to pharma and medical device industries

- PMLiVE

Novartis and Pfizer to collaborate on NASH combinations

Big pharma giants target nascent multi-billion market

- PMLiVE

GSK’s says depot HIV injection works over three years

The injection could rival Gilead’s single-tablet therapy

Neurodiversity, ADHD and work: Obstacles and opportunities

For ADHD awareness month this year our Associate Medical Writer, Alex Teahan, has written a piece surrounding ADHD and employment. He discusses the advantages and disadvantages of ADHD at work,...

Mednet

- PMLiVE

Budget 2018: UK life sciences sector delivers its verdict

UK Chancellor Philip Hammond delivered a budget that was broadly pro-business but contained mixed news for the life sciences industry, according to two industry bodies.The headline news of an additional...

- PMLiVE

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Both companies made same error in modelling, says NICE

- PMLiVE

US ‘unicorn’ Samumed on track with lead arthritis drug

Its injectable improved pain, joint function and patient global scores

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links